| Objective:Discussion human umbilical cord blood mesenchymal stem cells in vitro methods, cell growth curve, cell surface markers and other features of umbilical cord blood as a source of mesenchymal stem cells is feasible. Methods:Collecting cord blood, Percoll separating medium separation umbilical cord blood mesenchymal stem cells, adherent cultured human umbilical cord blood mesenchymal stem cells and passaged, growth curve, flow cytometry identified umbilical cord blood mesenchymal stem cell surface markers, the data Statistical analysis by statistical software SPSS17.0.Results:Cultured with adherent method can be successfully isolated from human umbilical cord blood, cultured MSCS, after repeated subculture exchange of medium and high purity can be obtained after the MSCS; human umbilical cord blood mesenchymal stem cell growth curve "S"-shaped In 1d after passage cells decreased, and then after a few days stay period, and then entered logarithmic growth phase, in which the first three most vigorous growth and proliferation of cells, with the increase in capacity of passages decreased; flow Cytometry detection of human umbilical cord blood mesenchymal stem cell surface markers showed CD90, CD44, CD34 expression rate consistent with human umbilical cord blood mesenchymal stem cell characteristics. Conclusion:Umbilical cord blood as a source of mesenchymal stem cells is feasible. Objective:To explore how to create a human liver cancer metastasis model. Methods: MHCC97-H high-metastatic human hepatocellular carcinoma beads cultured and passaged, and the mapping of the growth curve, preparation MHCC97-H cells were injected subcutaneously in nude mice to observe tumor formation in nude mice and metastasis cases, The data analyzed by statistical software SPSS 17.0. Results:MHCC97-H successful liver cell culture, grew well, is conducive to human liver cancer metastasis model; by drawing MHCC97-H hepatocellular carcinoma cells growth curve were obtained, MHCC97-H hepatocellular carcinoma cell growth curve "S"-shaped; control group, short of tumor in nude mice, tumor diameter, length, tumor was 100%; subcutaneous tumors in nude mice showed a gradual increasing trend in the experimental group compared with the control group by statistical treatment, there was significant differences (P <0.05), the earliest time of liver metastases 4 weeks, the earliest time of lung metastases 5 weeks. Conclusion:The human liver cancer metastasis model of successful model. Objective:To investigate the infusion of human umbilical cord blood mesenchymal stem cell growth and metastasis of liver cancer inhibition. Methods:Human umbilical cord blood mesenchymal stem cells in cell suspensions, infusion of human umbilical cord blood mesenchymal stem cells in human liver cancer metastasis model in nude mice to observe tumor formation in nude mice compared case and transfer case, identified in human liver by flow cytometry Cancer metastasis in nude mice model of liver cancer blood CD 133+stem cells, the data analyzed by statistical software SPSS 17.0. Results:The experimental form tumors in nude mice tumor formation time and the control group P<0.05, from tumor diameter compared with the control group was not significant; by observing the subcutaneous tumors in nude mice showed a gradual growth trend, first appeared in the liver metastases Time for the first 4 weeks, the earliest time of lung metastases for the first 6 weeks later than the control group, the third week compared with the control group showed no statistically significant tumor size, liver metastasis and lung metastasis rates are the same, and Fourth, fifth, six weeks of subcutaneous tumor size was less than the control group P<0.05; human umbilical cord blood mesenchymal stem cells can inhibit the growth and metastasis of liver cancer, which may be related to the inhibition of the CD 133+ stem cells on liver cancer. Conclusion:Infusion of human umbilical cord blood mesenchymal stem cells inhibit the growth and metastasis of hepatocellular carcinoma. |
PDF Full Text Request